Dementia in China: epidemiology, clinical management, and research advances.
By L. Jia, Meina Quan, Yue Fu, T. Zhao, Yan Li, Cuibai Wei, Yi Tang, Q. Qin, Fen Wang, Yuchen Qiao and 10 more. Lancet Neurology, 2020
676 citations recorded by the source corpus.
China has the largest population of patients with dementia in the world, imposing a heavy burden on the public and health care systems. More than 100 epidemiological studies on dementia have been done in China, but the estimates of the prevalence and incidence remain inconsistent because of the use of different sampling methods. Despite improved access to health services, inadequate diagnosis and management for dementia is still common, particularly in rural areas. The Chinese Government issued a new policy to increase care facilities for citizens older than 65 years, but most patients with dementia still receive care at home. Western medicines for dementia symptoms are widely used in China, but many patients choose Chinese medicines even though they have little evidence supporting efficacy. The number of clinical trials of Chinese and western medicines has substantially increased as a result of progress in research on new antidementia drugs but international multicentre studies are few in number. Efforts are needed to establish a national system of dementia care enhance training in dementia for health professionals, and develop global collaborations to prevent and cure this disease.
Subfields: Complementary and alternative medicine, Physiology, Psychiatry and Mental health
View Paper: https://www.semanticscholar.org/paper/a3478b74b9d8269388144b6d75b510067b3a3c71
Citations in the corpus
- Dementia prevention, intervention, and care: 2020 report of the Lancet Commission (2020, neutral): “30,32 These data highlight the need for more focused work in LMIC for more accurate estimates of risk and interventions tailored to each setting.”